Clinical Dosing Data and Pen-Based Interpretation Phase 2 Obesity Trial (48 Weeks) The pivotal Phase 2 trial demonstrated: Up to ~24% mean weight reduction Strong dose-response relationship Higher doses associated with greater metabolic improvement Reference: Clinical trial registry: Phase 2 Type 2 Diabetes Study Parallel metabolic trials demonstrated: Significant HbA1c reductions Improved fasting glucose Improved post-prandial glucose control Reduction in insulin resistance markers Reference: Coskun T et al., Cell Metabolism , 2022 Dose Escalation Strategy Across studies, retatrutide was not initiated at target doses
Serious Health Complications Linked to Wegovy Some Wegovy patients in Dallas-Fort Worth have reported having severe side effects and medical problems
it is not a substitute for professional medical consultation, diagnosis, or treatment
We are symptom-led
For patients with type 2 diabetes who are prescribed retatrutide off-label through compounding, some providers have successfully obtained prior authorization by documenting failed trials of metformin, an SGLT2 inhibitor, and at least one GLP-1 receptor agonist
Although these drugs are intended for long-term use, real-world discontinuation rates are high 39% go off the meds within three months and 50% within 12 months
